OR WAIT null SECS
Check out the latest features and columns!
March's Executive Profile features Davidek Herron, Global Head of Digital, Roche
Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day
Pharm Exec's 18th Annual Pipeline Report focuses on spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics
March 10, 2023
How platforms like ChatGPT could transform engagement models.
Region’s diversity plays against efforts to curtail counterfeit drugs.
New candidates are targeting cancer, infectious diseases, and RSV.
While KOLs have been present in healthcare marketing for some time, DOLs are now emerging.
March 08, 2023
Building on Organon’s prior FP2030 commitment, the company announces $30 million in new funding to fuel global action and community-driven solutions needed by the 121 million women and girls who experience unplanned pregnancies each year.
Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.
According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
March 07, 2023
Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.
March 06, 2023
Standard Media Index's latest data suggests that 2022 may have been a tipping point in the transition to digital pharma advertising.
Pharmaceutical companies are increasingly using radio advertising, both traditional and digital.